Ann: Appendix 4C and Quarterly update, page-5

My thinking...Long way off means not near term as previously touted. Data needs to be collected from enrollments, analysed, lodged and then assessed by independent body with possible further requests.
Based on the response delays to the first submission I am thinking 3 months after our 20 patient trial data is submitted for review/approval.

So based on all these variables I think early 2018. So I anticipate a significant ramp up in share price second half of this year.

I hope the results are good, otherwise forget about anything I have said.